Abstract
Purpose: The main purpose of this study was to analyze the effects and tolerability of Oxaliplatin-Vinorelbine combination on Platinum-resistant epithelial ovarian carcinoma (EOC) patients. Methods: A single centered retrospective study comprising of 34 patients was conducted, and all 34 patients were treated with Vinorelbine 30 mg/m 2 on day 1 and 8 along with Oxaliplatin 100 mg/m 2 on day 1 of 3 weeks treatment cycle following progressive platinum-resistant EOC. Results: The combination showed an overall response rate (ORR) of 18% (95% CI, 4.4 - 31.6) where 2 (6%) patients had complete response and 4 (12%) patients had partial response. Stable disease was observed in 9 (26%) patients and progressive disease in 19 (56%) patients. Median diseases free survival, median relapse free survival and median time to progression was 17.05 months, 4.4 months, and 1.25 months, respectively. Hematological toxicities were mild; only 1 (2.9%) patient had G3 anemia and major non-hematological toxicities include nausea-vomiting, diarrhea, constipation, hepatotoxicity, fatigueness and alopecia, which are mainly limited to G1-G2 and reversible. Conclusion: The effect of this combination is moderate as a second line treatment of platinum resistant EOC; however, in comparison with other regimens of Vinorelbine and Oxaliplatin, the activity is substandard but the toxicity profile is well tolerable. Further multicenter evaluation is needed for the better understanding of the therapeutic efficacy of the combination.
Highlights
Ovarian cancer is the most fatal gynecologic carcinoma around the world.[1, 2] Approximately 225,000 women are diagnosed for ovarian cancer per year and there is record of almost 1, 40,000 deaths worldwide out of this disease.[3, 4] Symptoms of the disease are not significant which may mimic other diseases conditions and cause delayed diagnosis.[5]
The main toxicity includes hematological toxicities, nausea-vomiting, diarrhea, constipation, hepatotoxicity, alopecia and fatigueness. 44% of the patients had anemia and among this G1 was commonly seen (29.4%). 44% and 35.3% patients had Leukopenia and neutropenia respectively which remain within G1 and G2. 70.6% patients suffered from nausea and vomiting but mainly G1(61.8%)
Diarrhea and constipation were observed in 41.15% and 32.2% patients respectively and in both G1 was common. 61.6% patient had alopecia but limited mainly within G1 and G2
Summary
Ovarian cancer is the most fatal gynecologic carcinoma around the world.[1, 2] Approximately 225,000 women are diagnosed for ovarian cancer per year and there is record of almost 1, 40,000 deaths worldwide out of this disease.[3, 4] Symptoms of the disease are not significant which may mimic other diseases conditions and cause delayed diagnosis.[5]. At present diversive active second - line agents are available for ovarian cancer treatment and clinicians are using these frequently.[15] But the result of these second-line treatments on survival is usually not upto the mark.[18] Single as well as combination chemotherapy regimens are being used for the above mentioned patients. These regimens seem to cause greater level of toxicity without enhancing its efficacy.[19, 20]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
